European journal of nuclear medicine and molecular imaging
Scalene muscle uptake: a potential pitfall in head and neck PET/CT. Eur J Nucl Med Mol Imaging. 2008 Jan; 35(1):89-94.
Scalene muscle uptake: a potential pitfall in head and neck PET/CT.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Reproducibility of tumor blood flow quantification with 15O-water PET. J Nucl Med. 2008 Oct; 49(10):1620-7.
Reproducibility of tumor blood flow quantification with 15O-water PET.
Rosica D, Cheng SC, Hudson M, Sakellis C, Van den Abbeele AD, Kim CK, Jacene HA
Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice. Nucl Med Commun. 2018 May; 39(5):417-422.
Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice.
Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations. Clin Genitourin Cancer. 2018 08; 16(4):e919-e926.
Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations.
F-18 FDG PET/CT in acute respiratory distress syndrome: a case report. Clin Nucl Med. 2004 Dec; 29(12):786-8.
F-18 FDG PET/CT in acute respiratory distress syndrome: a case report.
2-Deoxy-2-[18F] fluoro-D-glucose uptake in intercostal respiratory muscles on positron emission tomography/computed tomography: smokers versus nonsmokers. Mol Imaging Biol. 2004 Nov-Dec; 6(6):405-10.
2-Deoxy-2-[18F] fluoro-D-glucose uptake in intercostal respiratory muscles on positron emission tomography/computed tomography: smokers versus nonsmokers.
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009 May; 50 Suppl 1:122S-50S.
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
The importance of brown adipose tissue. N Engl J Med. 2009 Jul 23; 361(4):417-8; author reply 419-20.
McKay RR, Bossé D, Gray KP, Michaelson MD, Krajewski K, Jacene HA, Walsh M, Bellmunt J, Pomerantz M, Harshman LC, Choueiri TK
Clinical cancer research : an official journal of the American Association for Cancer Research
Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clin Cancer Res. 2018 09 01; 24(17):4081-4088.
Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases.
Zukotynski K, Lewis A, O'Regan K, Jacene H, Sakellis C, Krajewski K, Israel D
PET/CT and renal pathology: a blind spot for radiologists? Part 1, primary pathology. AJR Am J Roentgenol. 2012 Aug; 199(2):W163-7.
PET/CT and renal pathology: a blind spot for radiologists? Part 1, primary pathology.
Ha PK, Hdeib A, Goldenberg D, Jacene H, Patel P, Koch W, Califano J, Cummings CW, Flint PW, Wahl R, Tufano RP
Archives of otolaryngology--head & neck surgery
The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006 Jan; 132(1):12-6.
The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma.
Lucas RG, Jacene H, Harolds J, Barnes L, Maurer A
Nuclear medicine training for radiology residents: needs assessment survey. Acad Radiol. 2007 Mar; 14(3):301-5.
Nuclear medicine training for radiology residents: needs assessment survey.
Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4129-32.
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.
Baba S, Jacene HA, Engles JM, Honda H, Wahl RL
CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. J Nucl Med. 2010 Feb; 51(2):246-50.
CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies.
Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2008 Sep 01; 26(25):4172-9.
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.
Abbott A, Sakellis CG, Andersen E, Kuzuhara Y, Gilbert L, Boyle K, Kulke MH, Chan JA, Jacene HA, Van den Abbeele AD
Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division. J Nucl Med Technol. 2018 Sep; 46(3):237-244.
Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division.
177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med Technol. 2018 Sep; 46(3):245-246.
177Lu-DOTATATE Peptide Receptor Radionuclide Therapy.
Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018 12; 28(6):605-610.
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.
Hawryluk EB, O'Regan KN, Sheehy N, Guo Y, Dorosario A, Sakellis CG, Jacene HA, Wang LC
Journal of the American Academy of Dermatology
Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. J Am Acad Dermatol. 2013 Apr; 68(4):592-599.
Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center.
2018 SNMMI Highlights Lecture: General Nuclear Medicine. J Nucl Med. 2018 Oct; 59(10):7N-13N.
2018 SNMMI Highlights Lecture: General Nuclear Medicine.
Otolaryngologic clinics of North America
Imaging of parathyroid glands. Otolaryngol Clin North Am. 2010 Apr; 43(2):399-415, x.
Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, Kahn Y, Spira A, Dancey J, Iacobuzio-Donahue C, Donehower RC, Carducci M, Rudek MA, Hidalgo M
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2010 Dec; 9(5):297-304.
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
Díaz-Montes TP, Jacene HA, Wahl RL, Bristow RE
Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac. Gynecol Oncol. 2005 Sep; 98(3):510-2.
Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac.
Jacene HA, Youn T, DiPiro PJ, Hu J, Cheng SC, Franchetti Y, Shah H, Bellon JR, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth J, Yeh E, Overmoyer B
Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade. Clin Breast Cancer. 2019 04; 19(2):146-155.
Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade.
Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT. Clin Nucl Med. 2006 Jul; 31(7):379-81.
Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT.
Hobbs RF, Baechler S, Wahl RL, He B, Song H, Esaias CE, Frey EC, Jacene H, Sgouros G
Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy. J Nucl Med. 2010 Mar; 51(3):368-75.
Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy.
Extraosseous Colonic Uptake of 99mTc-MDP Associated With Iodinated Contrast CT. Clin Nucl Med. 2019 May; 44(5):414-416.
Extraosseous Colonic Uptake of 99mTc-MDP Associated With Iodinated Contrast CT.
Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS
European journal of cancer (Oxford, England : 1990)
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019 06; 114:107-116.
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
Associate Professor of Obstetrics, Gynecology and Reproductive Biology
Assistant Professor of Radiation Oncology
Steven E. Seltzer, MD, Professor of Radiology
Instructor in Obstetrics, Gynecology and Reproductive Biology
No delayed imaging or CCK administration is needed in most cases when bowel excretion does not occur but gallbladder fills promptly. Ann Nucl Med. 2019 Oct; 33(10):740-745.
No delayed imaging or CCK administration is needed in most cases when bowel excretion does not occur but gallbladder fills promptly.
Nakhlis F, Regan MM, Chun YS, Dominici LS, Caterson S, Bellon JR, Warren L, Yeh ED, Jacene HA, King TA, Overmoyer B
Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience. Breast J. 2020 03; 26(3):384-390.
Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience.
2019 SNMMI Highlights Lecture: General Nuclear Medicine and Molecular Imaging. J Nucl Med. 2019 Oct; 60(10):13N-18N.
2019 SNMMI Highlights Lecture: General Nuclear Medicine and Molecular Imaging.
Thomas R, Shinagare AB, Rosenthal MH, Lee B, Jacene HA, Johnston MA, Overmoyer BA
Computed tomographic assessment of lean body mass in patients on selective androgen receptor modulator. Clin Imaging. 2020 02; 59(2):100-103.
Computed tomographic assessment of lean body mass in patients on selective androgen receptor modulator.
Robertson MS, Sakellis CG, Hyun H, Jacene HA
Extraprostatic Uptake of 18F-Fluciclovine: Differentiation of Nonprostatic Neoplasms From Metastatic Prostate Cancer. AJR Am J Roentgenol. 2020 03; 214(3):641-648.
Extraprostatic Uptake of 18F-Fluciclovine: Differentiation of Nonprostatic Neoplasms From Metastatic Prostate Cancer.
Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867.
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
Jacene HA, DiPiro PJ, Bellon J, Hu J, Cheng SC, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth JM, Yeh E, Overmoyer B
Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. Breast Cancer Res Treat. 2020 Jun; 181(2):383-390.
Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
Hurwitz M, Buscombe JR, Jacene HA, Klitzke AK, Lamonica D, Lu Y, Pryma DA, Rohren EM, Speer TW, Subramaniam RM, Thompson HM, Tomblyn MB, Wong WW, Xiao Y, Banks KP, Brown RKJ
ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223. Am J Clin Oncol. 2020 08; 43(8):539-544.
ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223.
Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, Lako A, Ciantra Z, Weirather JL, Criscitiello S, Luoma A, Chau N, Lorch J, Kass JI, Annino D, Goguen L, Desai A, Ross B, Shah HJ, Jacene HA, Margalit DN, Tishler RB, Wucherpfennig KW, Rodig SJ, Uppaluri R, Haddad RI
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570.
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
2020 SNMMI Highlights Lecture: General Nuclear Medicine and Molecular Imaging. J Nucl Med. 2020 10; 61(10):17N-23N.
2020 SNMMI Highlights Lecture: General Nuclear Medicine and Molecular Imaging.
FDG PET for Assessment of Autologous Stem Cell Transplantation. Semin Nucl Med. 2021 07; 51(4):380-391.
FDG PET for Assessment of Autologous Stem Cell Transplantation.
Intercostal Brown Adipose Tissue on FDG PET/CT. AJR Am J Roentgenol. 2021 10; 217(4):1007.
Intercostal Brown Adipose Tissue on FDG PET/CT.
Ulaner GA, Jacene HA, Parihar AS, Groheux D
Evidence-Based Best Practices: 18F-FDG PET Staging of Newly Diagnosed Breast Cancer. Clin Nucl Med. 2021 07 01; 46(7):569-570.
Evidence-Based Best Practices: 18F-FDG PET Staging of Newly Diagnosed Breast Cancer.
Jacene H, Liu M, Cheng SC, Abbott A, Dubey S, McCall K, Young D, Johnston M, Van den Abbeele AD, Overmoyer B
Imaging Androgen Receptors in Breast Cancer with 18F-Fluoro-5a-Dihydrotestosterone PET: A Pilot Study. J Nucl Med. 2022 Jan; 63(1):22-28.
Imaging Androgen Receptors in Breast Cancer with 18F-Fluoro-5a-Dihydrotestosterone PET: A Pilot Study.
Karls S, Gold R, Kravets S, Wang Y, Cheng S, Perez K, Chan J, Jacene H
Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms. Ann Nucl Med. 2021 Sep; 35(9):1066-1077.
Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms.
Hirko KA, Regan MM, Remolano MC, Schlossman J, Harrison B, Yeh E, Jacene H, Nakhlis F, Block C, Rosenbluth JM, Garrido-Castro AC, Overmoyer BA
Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer. Am J Clin Oncol. 2021 09 01; 44(9):449-455.
Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer.
Wahl RL, Frey EC, Jacene HA, Kahl BS, Piantadosi S, Bianco JA, Hammes RJ, Jung M, Kasecamp W, He B, Sgouros G, Flinn IW, Swinnen LJ
Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. Cancers (Basel). 2021 Jun 06; 13(11).
Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
PET Imaging for Hematologic Malignancies. Radiol Clin North Am. 2021 Sep; 59(5):705-723.
PET Imaging for Hematologic Malignancies.
Yeh E, Rives A, Nakhlis F, Bay C, Harrison BT, Bellon JR, Remolano MC, Jacene H, Giess C, Overmoyer B
MRI Changes in Breast Skin Following Preoperative Therapy for Patients with Inflammatory Breast Cancer. Acad Radiol. 2022 05; 29(5):637-647.
MRI Changes in Breast Skin Following Preoperative Therapy for Patients with Inflammatory Breast Cancer.
Hughes NM, Hammer MM, Awad MM, Jacene HA
Radiation Recall Pneumonitis on FDG PET/CT Triggered by COVID-19 Vaccination. Clin Nucl Med. 2022 Mar 01; 47(3):e281-e283.
Radiation Recall Pneumonitis on FDG PET/CT Triggered by COVID-19 Vaccination.
Pandit-Taskar N, Iravani A, Lee D, Jacene H, Pryma D, Hope T, Saboury B, Capala J, Wahl RL
Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. J Nucl Med. 2021 Dec; 62(Suppl 3):60S-72S.
Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.
Wahl RL, Sgouros G, Iravani A, Jacene H, Pryma D, Saboury B, Capala J, Graves SA
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns. J Nucl Med. 2021 Dec; 62(Suppl 3):23S-35S.
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns.
Shah H, Wang Y, Cheng SC, Gunasti L, Chen YH, Lako A, Guenette J, Rodig S, Jo VY, Uppaluri R, Haddad R, Schoenfeld JD, Jacene HA
JAMA otolaryngology-- head & neck surgery
Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. JAMA Otolaryngol Head Neck Surg. 2022 Mar 01; 148(3):268-276.
Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers.
Imaging for Radiation Planning in Breast Cancer. Semin Nucl Med. 2022 09; 52(5):542-550.
Imaging for Radiation Planning in Breast Cancer.
Ng TSC, Hu H, Kronister S, Lee C, Li R, Gerosa L, Stopka SA, Burgenske DM, Khurana I, Regan MS, Vallabhaneni S, Putta N, Scott E, Matvey D, Giobbie-Hurder A, Kohler RH, Sarkaria JN, Parangi S, Sorger PK, Agar NYR, Jacene HA, Sullivan RJ, Buchbinder E, Mikula H, Weissleder R, Miller MA
Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. Sci Adv. 2022 Apr 29; 8(17):eabl6339.
Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy.
Hussain M, Carducci MA, Clarke N, Fenton SE, Fizazi K, Gillessen S, Jacene H, Morris MJ, Saad F, Sartor O, Taplin ME, Vapiwala N, Williams S, Sweeney C
Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? J Clin Oncol. 2022 09 10; 40(26):3011-3014.
Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?
Perez K, Jacene H, Hornick JL, Ma C, Vaz N, Brais LK, Alexander H, Baddoo W, Astone K, Esplin ED, Garcia J, Halperin DM, Kulke MH, Chan JA
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2022 09 01; 29(9):533-544.
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
Wrenn SM, Moore AL, Shah HJ, Barletta JA, Vaidya A, Kilbridge KL, Doherty GM, Jacene HA, Nehs MA
Higher SUVmax on FDG-PET is associated with shorter survival in adrenocortical carcinoma. Am J Surg. 2023 02; 225(2):309-314.
Higher SUVmax on FDG-PET is associated with shorter survival in adrenocortical carcinoma.
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2022 11; 22(11):1163-1175.
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.
177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy. J Nucl Med Technol. 2022 09; 50(3):213-214.
177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy.
Shah H, Sundar R, Prado DEA, Dong JW, Chow DZ, Kuo B, Voss SD, Jacene HA, Robertson MS, Ng TSC
Standard Adult Gastric Emptying Scintigraphy Criteria Is Applicable for Partial Meal Ingestion. Dig Dis Sci. 2023 02; 68(2):541-553.
Standard Adult Gastric Emptying Scintigraphy Criteria Is Applicable for Partial Meal Ingestion.
Kako B, Dong JW, An BP, McLoud TC, Durfee SM, Jacene HA, Chow DZ, Wang Y, Hyun H, Ng TSC
Key Factors to Attract More U.S. Diagnostic Radiology Residents into the Field of Nuclear Medicine and Molecular Imaging: A National Survey. Acad Radiol. 2023 04; 30(4):755-762.
Key Factors to Attract More U.S. Diagnostic Radiology Residents into the Field of Nuclear Medicine and Molecular Imaging: A National Survey.
177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med Technol. 2022 09; 50(3):203-204.
Zeman MN, Akin EA, Merryman RW, Jacene HA
Interim FDG-PET/CT for Response Assessment of Lymphoma. Semin Nucl Med. 2023 05; 53(3):371-388.
Interim FDG-PET/CT for Response Assessment of Lymphoma.
Merryman RW, Redd RA, Taranto E, Ahmed G, Jeter E, McHugh KM, Brown JR, Crombie JL, Davids MS, Fisher DC, Freedman AS, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Jacene H, Park H, Dahi PB, Nieto Y, Joyce RM, Chen YB, Shipp MA, Herrera AF, Armand P
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2023 09 12; 7(17):4748-4759.
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schöder H, Wan S, Wester HJ, Hope TA, Herrmann K
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023 04; 50(5):1466-1486.
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.
Ravi P, Whelpley B, Kelly E, Wolanski A, Ritzer J, Robertson M, Shah H, Morgans AK, Wei XX, Sunkara R, Pomerantz M, Taplin ME, Kilbridge KL, Choudhury AD, Jacene H
Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges. J Nucl Med. 2023 03; 64(3):349-350.
Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges.
Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, Graham MM, Jacene HA, Heath CL, Mittra ES, Wright CL, Fendler WP, Herrmann K, Taïeb D, Kjaer A
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med. 2023 02; 64(2):204-210.
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors.
Merryman RW, Michaud L, Redd R, Mondello P, Park H, Spilberg G, Robertson M, Taranto E, Ahmed G, Chase M, Jeter E, Ahn IE, Brown JR, Crombie J, Davids MS, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Salles G, Zelenetz AD, Armand P, Schöder H, Jacene H
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma. Hemasphere. 2023 Feb; 7(2):e826.
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.
Vaz N, Franquet E, Heidari P, Chow DZ, Jacene HA, Ng TSC
COVID-19: Findings in nuclear medicine from head to toe. Clin Imaging. 2023 Jul; 99:10-18.
COVID-19: Findings in nuclear medicine from head to toe.
McCall KC, Liu M, Cheng SC, Abbott A, Dubey S, Young D, Johnston M, Van den Abbeele AD, Overmoyer B, Jacene H
Report on the PET/CT Image-Based Radiation Dosimetry of [18F]FDHT in Women, a Validated Imaging Agent with New Applications for Evaluation of Androgen Receptor Status in Women with Metastatic Breast Cancer. J Nucl Med Technol. 2023 Sep; 51(3):204-210.
Report on the PET/CT Image-Based Radiation Dosimetry of [18F]FDHT in Women, a Validated Imaging Agent with New Applications for Evaluation of Androgen Receptor Status in Women with Metastatic Breast Cancer.
Litton JK, Regan MM, Pusztai L, Rugo HS, Tolaney SM, Garrett-Mayer E, Amiri-Kordestani L, Basho RK, Best AF, Boileau JF, Denkert C, Foster JC, Harbeck N, Jacene HA, King TA, Mason G, O'Sullivan CC, Prowell TM, Richardson AL, Sepulveda KA, Smith ML, Tjoe JA, Turashvili G, Woodward WA, Butler LP, Schwartz EI, Korde LA
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. J Clin Oncol. 2023 09 20; 41(27):4433-4442.
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
Hope TA, Antonarakis ES, Bodei L, Calais J, Iravani A, Jacene H, Koo PJ, Morgans AK, Osborne JR, Tagawa ST, Taplin ME, Sartor O, Morris MJ
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy. J Nucl Med. 2023 09; 64(9):1417-1423.
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy.
Mario J, Dietsche E, Halpern J, Schneider A, Sakellis C, Jacene H, Shah H
Radiographics : a review publication of the Radiological Society of North America, Inc
Hepatobiliary Scintigraphy: A Case-based Review. Radiographics. 2023 09; 43(9):e220104.
Hepatobiliary Scintigraphy: A Case-based Review.
Vaz N, Dietsche E, Mooney MA, Choudhury AD, Jacene HA
Late Subacute Cerebral Hematoma Mimicking a Metastasis on PSMA PET/CT. Clin Nucl Med. 2024 Feb 01; 49(2):e70-e72.
Late Subacute Cerebral Hematoma Mimicking a Metastasis on PSMA PET/CT.
Mehrtash A, Ziegler E, Idris T, Somarouthu B, Urban T, LaCasce AS, Jacene H, Van Den Abbeele AD, Pieper S, Harris G, Kikinis R, Kapur T
Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
Evaluation of mediastinal lymph node segmentation of heterogeneous CT data with full and weak supervision. Comput Med Imaging Graph. 2024 01; 111:102312.
Evaluation of mediastinal lymph node segmentation of heterogeneous CT data with full and weak supervision.
The Current and Future Roles of Precision Oncology in Advanced Breast Cancer. J Nucl Med. 2024 03 01; 65(3):349-356.
The Current and Future Roles of Precision Oncology in Advanced Breast Cancer.
Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024 04; 211(4):526-532.
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024 04; 211(4):518-525.
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. J Urol. 2024 04; 211(4):509-517.
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
Choudhury AD, Kwak L, Cheung A, Allaire KM, Marquez J, Yang DD, Tripathi A, Kilar JM, Flynn M, Maynard B, Reichel R, Pace AF, Chen BK, Van Allen EM, Kilbridge K, Wei XX, McGregor BA, Pomerantz MM, Bhatt RS, Sweeney CJ, Bubley GJ, Jacene HA, Taplin ME, Huang FW, Harshman LC, Fong L
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer. Cancer Immunol Res. 2024 Jun 04; 12(6):704-718.
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.
The Age of Theragnostics. PET Clin. 2024 Jul; 19(3):xiii.
Neuroendocrine Tumors: Diagnostics. PET Clin. 2024 Jul; 19(3):325-339.
Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, Jacene H, Rubio IT, Schoones JW, Peeters MV, Poortmans P, Mann RM, Graff SL, Dibble EH, de Geus-Oei LF
Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA). Eur J Nucl Med Mol Imaging. 2024 Jul; 51(9):2706-2732.
Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).
Groheux D, Vaz SC, Ulaner GA, Cook GJR, Woll JPP, Mann RM, Poortmans P, Cardoso F, Jacene H, Graff SL, Rubio IT, Peeters MV, Dibble EH, de Geus-Oei LF
Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines. Eur J Nucl Med Mol Imaging. 2024 Jul; 51(9):2701-2705.
Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines.
Alpha-emitter Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors. PET Clin. 2024 Jul; 19(3):341-349.
Alpha-emitter Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors.
Gupta S, Green-Lingren O, Bhimaniya S, Krokhmal A, Jacene H, Ostermann M, Chicklore S, Sprangers B, Deroose CM, Herrmann SM, Wells SL, Kaunfer SA, Ortega JL, García-Carro C, Bold M, Chen KL, Sise ME, Heidari P, Pak WLW, Lee MD, Beckerman P, Eshet Y, Hsu RK, Hernandez Pampaloni M, Rashidi A, Avril N, Donley V, Mithani Z, Kuker R, Awiwi MO, Wang MX, Shah SI, Weintraub MD, Schoder H, Chowdhury RB, Seethapathy H, Reynolds KL, Soler MJ, Abudayyeh A, Glezerman I, Leaf DE
F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor-associated acute kidney injury. J Clin Invest. 2024 Aug 08; 134(18).
F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor-associated acute kidney injury.
Trinh K, Chow DZ, Park H, Habib U, Offit L, Franquet E, Almeida RR, Wang Y, Borges N, Jamal F, Jacene HA, Heidari P, Ng TSC
Evaluating the Added Value of Concurrent Contrast-enhanced Diagnostic CT for PSMA-PET/CT Interpretation. Acad Radiol. 2025 Jan; 32(1):275-286.
Evaluating the Added Value of Concurrent Contrast-enhanced Diagnostic CT for PSMA-PET/CT Interpretation.
Maurer K, Grabski IN, Houot R, Gohil SH, Miura S, Redd R, Lyu H, Lu W, Arihara Y, Budka J, McDonough M, Ansuinelli M, Reynolds C, Jacene H, Li S, Livak KJ, Ritz J, Miles B, Mattie M, Neuberg DS, Irizarry RA, Armand P, Wu CJ, Jacobson C
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma. Blood. 2024 Dec 12; 144(24):2490-2502.
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma.
Groheux D, Vaz SC, Poortmans P, Mann RM, Ulaner GA, Cook GJR, Hindié E, Pilkington Woll JP, Jacene H, Rubio IT, Vrancken Peeters MJ, Dibble EH, de Geus-Oei LF, Graff SL, Cardoso F
Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines. Breast. 2024 Dec; 78:103806.
Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines.
Robertson MS, Wang Y, Cheng S, Park H, Glomski S, Harshman LC, Pace A, Kilar J, Flynn M, Gilbert L, Choudhury AD, Jacene H
Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone. Radiol Med. 2025 Jan; 130(1):132-142.
Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone.
Solving Challenging Puzzles: Heather Jacene Talks with Johannes Czernin About Leadership in Clinical Nuclear Medicine and the SNMMI. J Nucl Med. 2025 Jan 03; 66(1):1-3.
Solving Challenging Puzzles: Heather Jacene Talks with Johannes Czernin About Leadership in Clinical Nuclear Medicine and the SNMMI.
Tirumani SH, Jagannathan JP, Krajewski KM, Shinagare AB, Jacene H, Ramaiya NH
Imatinib and beyond in gastrointestinal stromal tumors: A radiologist's perspective. AJR Am J Roentgenol. 2013 Oct; 201(4):801-10.
Imatinib and beyond in gastrointestinal stromal tumors: A radiologist's perspective.
Rami A, Rashid NS, Zhong C, Xie W, Stoltenberg H, Wheeler EJ, Wolanski A, Ritzer J, Choudhury AD, Taplin ME, Jacene H, Tewari AK, Ravi P
Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancer. ESMO Open. 2025 Feb; 10(2):104131.
Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancer.
Mohammadi S, Pompa IR, Haberman V, Kako B, Lee RJ, Saylor PJ, Gao X, Esfahani SA, Heidari P, Ravi P, Sayan M, Efstathiou JA, Jacene HA, Kamran SC, Ng TSC
Combination Metastasis-Targeted External Beam Radiation Therapy With 177Lu-PSMA-617 in Patients With Advanced Castration-Resistant Prostate Cancer. Pract Radiat Oncol. 2025 Nov-Dec; 15(6):e597-e605.
Combination Metastasis-Targeted External Beam Radiation Therapy With 177Lu-PSMA-617 in Patients With Advanced Castration-Resistant Prostate Cancer.
Rashid NS, Rami A, Lang M, Stoltenberg H, Wolanski A, Ritzer J, Jacene H, Ravi P
Activity of 177Lu-PSMA-617 in Patients With Advanced Prostate Cancer and Brain Metastases. Clin Genitourin Cancer. 2025 Apr; 23(2):102309.
Activity of 177Lu-PSMA-617 in Patients With Advanced Prostate Cancer and Brain Metastases.
Yeh ED, Jacene HA, Bellon JR, Nakhlis F, Birdwell RL, Georgian-Smith D, Giess CS, Hirshfield-Bartek J, Overmoyer B, Van den Abbeele AD
What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. Radiographics. 2013 Nov-Dec; 33(7):2003-17.
What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach.
Al-Ibraheem A, Scott AM, Abdlkadir AS, Vrachimis A, Lamoureux F, Trujillo PB, Bailey DL, More S, Giammarile F, Kumar R, Nonnekens J, Cutler CS, Urbain JC, Dibble EH, Sathekge MM, Bomanji J, Cerci JJ, Thomas E, Small W, Louw L, O JH, Lee ST, Nadel H, Jacene H, Watabe T, Bom HH, Bouyoucef SE, Weston C, Wadsley J, Irwin AG, Croasdale J, Zanzonico P, Paez D, Ghesani M
Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative. J Nucl Med. 2025 May 01; 66(5):757-763.
Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative.
Losee M, Kavanaugh M, Liu M, Borges N, Haberman V, Ritzer J, Wolanski A, Bhimaniya S, Choudhury AD, Hyun H, Stoltenberg H, Kilbridge KL, Morgans A, Pomerantz M, Robertson M, Sakellis C, Shah H, Taplin ME, Wei XX, Ng T, Ravi P, Jacene H
Outcome of Subsequent Therapies After 177Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience. Prostate. 2025 Jun; 85(8):742-748.
Outcome of Subsequent Therapies After 177Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience.
Groheux D, Vaz SC, de Geus-Oei LF, Dibble EH, Ulaner GA, Cook GJR, Hindié E, Poortmans P, Mann RM, Jacene H, Pilkington Woll JP, Rubio IT, Vrancken Peeters MJ, Graff SL, Cardoso F
[18F]-Labeled Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Staging and Restaging Patients With Breast Cancer. J Clin Oncol. 2025 Jun 10; 43(17):1942-1947.
[18F]-Labeled Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Staging and Restaging Patients With Breast Cancer.
Ng TSC, Liu M, Robertson M, Könik A, Cheng SC, Bakht MK, Harrington K, Wolanski A, Gilbert L, Preston M, Mossanen M, Beltran H, Hirsch MS, Sonpavde G, Jacene HA
A pilot study of [18F]F-fluciclovine positron emission tomography/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy. Eur J Nucl Med Mol Imaging. 2025 Sep; 52(11):4092-4101.
A pilot study of [18F]F-fluciclovine positron emission tomography/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy.
Pyo J, Won Kim K, Jacene HA, Sakellis CG, Brown JR, Van den Abbeele AD
End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res. 2013 Dec 01; 19(23):6566-77.
End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis.
Semaan K, Nawfal R, Canniff J, Savignano H, Seo JH, Siegmund SE, Wu SJ, Rotow JK, Lee GM, El Hajj Chehade R, Zhang Z, Gulati GS, Phillips N, Lee GG, French CA, Hirsch MS, Jacene HA, Choudhury AD, Choueiri TK, Freedman ML, Baca SC, Berchuck JE
Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer. NPJ Precis Oncol. 2025 Jul 09; 9(1):233.
Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer.
Rami A, Zhong C, Muniz M, Xie W, Khorasanchi A, Gallagher J, Mohammadi S, Fein D, Voter AF, Stoltenberg H, Gopalakrishan D, Yang Y, Ng TSC, Gafita A, Childs DS, Jacene H, Ravi P
Race and Outcomes to [177Lu]Lu-PSMA-617 in Advanced Prostate Cancer. Cancers (Basel). 2025 Jun 12; 17(12).
Race and Outcomes to [177Lu]Lu-PSMA-617 in Advanced Prostate Cancer.
Borges N, Losee M, Liu M, Cheng SC, Könik A, Ritzer J, Wolanski A, Ng TSC, Choudhury AD, Taplin ME, Ravi P, Jacene H
Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging. Eur J Nucl Med Mol Imaging. 2026 Feb; 53(3):1559-1569.
Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging.
Saboo SS, Ramaiya N, Jacene H, Rainville I, Diller L, Hornick JL, George S
Synchronous small bowel and atypical primary leiomyosarcoma of inferior vena cava in a patient with RB1 mutation. Abdom Imaging. 2014 Feb; 39(1):33-9.
Synchronous small bowel and atypical primary leiomyosarcoma of inferior vena cava in a patient with RB1 mutation.
Krasnow N, Maurer K, Song C, Rhoades J, Xiong K, Crnjac A, Blewett T, Gao L, Jacene H, Merryman R, Gohil SH, Duffy C, Guerrero LI, Dela Cruz J, McDonough M, Wolff JO, Redd R, Mattie M, Miles B, Makrigiorgos GM, Neuberg DS, Rodig SJ, Armand P, Jacobson C, Adalsteinsson VA, Wu CJ
Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma. Blood Adv. 2025 Nov 11; 9(21):5539-5545.
Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma.
Hazut Krauthammer S, Xie W, LaBrecque N, Arsenault L, Kabarame L, Shah H, Berg S, McGregor B, Serzan M, Xu W, Viswanathan SR, Wei XX, Choueiri TK, Jacene H, Ravi P
LASER: A Phase 2 Trial of 177Lu-PSMA-617 as Systemic Therapy for RCC. J Nucl Med. 2026 Apr 01; 67(4):501-505.
LASER: A Phase 2 Trial of 177Lu-PSMA-617 as Systemic Therapy for RCC.
Uribe C, Iravani A, Savir-Baruch B, Jacene H, Graves SA, Dewaraja YK, Heath CL, Hope TA
Summary: SNMMI/ACNM Procedure Standard for Posttreatment Imaging of 177Lu-Based Radiopharmaceuticals. J Nucl Med. 2025 Oct 01; 66(10):1528-1537.
Summary: SNMMI/ACNM Procedure Standard for Posttreatment Imaging of 177Lu-Based Radiopharmaceuticals.
Hennessy MA, Gatsonis C, Jacene H, Connolly RM, Burnette BL, Stringer-Reasor EM, Romanoff J, Taurone A, O'Sullivan CC, Le-Petross HT, Stearns V, Fowler AM, Tang SC, Sepulveda KA, DeMichele AM, Mankoff DA, Wolff AC
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial). Future Oncol. 2025 Nov; 21(26):3377-3384.
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial).
Jacene HA, Urbain JL, Lewis JS, Nadel H, Bolin JD, Cutler CS
Radiopharmaceutical Therapy: Rapid Growth, Rising Challenges, and the Critical Need for Expertise. J Nucl Med. 2025 Dec 03; 66(12):1871-1879.
Radiopharmaceutical Therapy: Rapid Growth, Rising Challenges, and the Critical Need for Expertise.
Domachevsky L, Jacene HA, Sakellis CG, Kim CK
Postradiation changes in tissues: evaluation by imaging studies with emphasis on fluorodeoxyglucose-PET/computed tomography and correlation with histopathologic findings. PET Clin. 2014 Apr; 9(2):217-35.
Postradiation changes in tissues: evaluation by imaging studies with emphasis on fluorodeoxyglucose-PET/computed tomography and correlation with histopathologic findings.
Gynecologic oncologic imaging with PET/CT. Semin Nucl Med. 2014; 44(6):461-78.
Gynecologic oncologic imaging with PET/CT.
Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA
Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015 Mar-Apr; 35(2):424-37.
Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events.
Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma. PET Clin. 2015 Apr; 10(2):207-25.
Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
Warren LE, Guo H, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR
Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. Breast Cancer Res Treat. 2015 May; 151(1):225-32.
Inflammatory breast cancer and development of brain metastases: risk factors and outcomes.
Radionuclide therapy for osseous metastases in prostate cancer. Semin Nucl Med. 2015 Jan; 45(1):66-80.
Radionuclide therapy for osseous metastases in prostate cancer.
Tirumani SH, Sakellis C, Jacene H, Shinagare AB, Munshi NC, Ramaiya NH, Van den Abbeele AD
Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome. Clin Nucl Med. 2016 Jan; 41(1):e7-13.
Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome.
Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. Ann Surg Oncol. 2015 Aug; 22(8):2483-91.
Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management.
Mandelker D, Dal Cin P, Jacene HA, Armand P, Stone RM, Lindeman NI
Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. Exp Hematol Oncol. 2015; 4:30.
Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing.
Van den Abbeele AD, Krajewski KM, Tirumani SH, Fennessy FM, DiPiro PJ, Nguyen QD, Harris GJ, Jacene HA, Lefever G, Ramaiya NH
Journal of the American College of Radiology : JACR
Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. J Am Coll Radiol. 2016 Apr; 13(4):365-71.
Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center.
Jacene H, Crandall J, Kasamon YL, Ambinder RF, Piantadosi S, Serena D, Kasecamp W, Wahl RL
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. Mol Imaging Biol. 2017 06; 19(3):429-436.
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.
Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, Hoos A, Barrington SF, Armand P
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016 11 24; 128(21):2489-2496.
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.
Mingos M, Howard S, Giacalone N, Kozono D, Jacene H
Systemic Immune Response to Vaccination on FDG-PET/CT. Nucl Med Mol Imaging. 2016 Dec; 50(4):358-361.
Systemic Immune Response to Vaccination on FDG-PET/CT.
Kasamon YL, Jacene HA, Swinnen LJ, Popplewell L, Link BK, Habermann TM, Herman JM, Jones RJ, Ambinder RF
Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL). J Clin Oncol. 2011 May 20; 29(15_suppl):8039.
Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL).
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 01 12; 376(2):125-135.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Swinnen LJ, Flinn IW, Kahl BS, Frey E, Rogers K, Jung M, Jacene H, Wahl RL
Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol. 2008 May 20; 26(15_suppl):8565.
Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
McKay RR, Jacobus S, Fiorillo M, Ledet EM, Cotogna PM, Steinberger AE, Jacene HA, Sartor O, Taplin ME
Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. Clin Genitourin Cancer. 2017 04; 15(2):e289-e298.
Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy.
Jacene HA, Filice R, Kasecamp W, Wahl RL
Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007 Nov; 48(11):1767-76.
Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
He B, Du Y, Segars WP, Wahl RL, Sgouros G, Jacene H, Frey EC
Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. Med Phys. 2009 Feb; 36(2):612-9.
Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake.
O JH, Jacene H, Luber B, Wang H, Huynh MH, Leal JP, Wahl RL
Quantitation of Cancer Treatment Response by 18F-FDG PET/CT: Multicenter Assessment of Measurement Variability. J Nucl Med. 2017 09; 58(9):1429-1434.
Quantitation of Cancer Treatment Response by 18F-FDG PET/CT: Multicenter Assessment of Measurement Variability.
Jacene HA, Ishimori T, Engles JM, Leboulleux S, Stearns V, Wahl RL
Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med. 2006 Jun; 47(6):950-6.
Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies.
Molecular imaging training course debuts. J Nucl Med. 2012 Jan; 53(1):16NA.
Molecular imaging training course debuts.
Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, Hidalgo M
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009 Jun 01; 27(16):2697-704.
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Jacene HA, Ginsburg P, Kwon J, Nguyen GC, Montgomery EA, Bayless TM, Wahl RL
Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. J Nucl Med. 2009 Nov; 50(11):1751-9.
Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT.
Nakhlis F, Regan MM, Warren LE, Bellon JR, Hirshfield-Bartek J, Duggan MM, Dominici LS, Golshan M, Jacene HA, Yeh ED, Mullaney EE, Overmoyer B
The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2017 Sep; 24(9):2563-2569.
The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
He B, Wahl RL, Du Y, Sgouros G, Jacene H, Flinn I, Frey EC
Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--Monte Carlo simulation studies. IEEE Trans Med Imaging. 2008 Apr; 27(4):521-30.
Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--Monte Carlo simulation studies.
Recurrent or residual hyperparathyroidism and thyroid cancer effectively evaluated with scintigraphy. Otolaryngol Clin North Am. 2008 Dec; 41(6):1117-33, viii-ix.
Recurrent or residual hyperparathyroidism and thyroid cancer effectively evaluated with scintigraphy.
He B, Wahl RL, Sgouros G, Du Y, Jacene H, Kasecamp WR, Flinn I, Hammes RJ, Bianco J, Kahl B, Frey EC
Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies. Med Phys. 2009 May; 36(5):1595-601.
Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies.
Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M
The Journal of clinical endocrinology and metabolism
Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab. 2009 Apr; 94(4):1310-6.
Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer.
Bonekamp D, Jacene H, Bartelt D, Aygun N
Conversion of FDG PET activity of fibrous dysplasia of the skull late in life mimicking metastatic disease. Clin Nucl Med. 2008 Dec; 33(12):909-11.
Conversion of FDG PET activity of fibrous dysplasia of the skull late in life mimicking metastatic disease.
Melton GB, Lavely WC, Jacene HA, Schulick RD, Choti MA, Wahl RL, Gearhart SL
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg. 2007 Aug; 11(8):961-9; discussion 969.
Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy.
Zukotynski K, Lewis A, O'Regan K, Jacene H, Sakellis C, Almodovar S, Israel D
PET/CT and renal pathology: a blind spot for radiologists? Part 2--lymphoma, leukemia, and metastatic disease. AJR Am J Roentgenol. 2012 Aug; 199(2):W168-74.
PET/CT and renal pathology: a blind spot for radiologists? Part 2--lymphoma, leukemia, and metastatic disease.
Kamran SC, Jacene HA, Chen YH, Mauch PM, Ng AK
Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD?×?two cycles followed by FDG-PET/CT restaging and 20?Gy of involved-site radiotherapy. Leuk Lymphoma. 2018 06; 59(6):1384-1390.
Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD?×?two cycles followed by FDG-PET/CT restaging and 20?Gy of involved-site radiotherapy.
Alabed YZ, Cheng SC, Mudge C, Sakellis C, Van den Abbeele AD, Campos SM, Jacene HA
Current problems in diagnostic radiology
Surveillance Imaging in Patients With Endometrial Cancer in First Remission. Curr Probl Diagn Radiol. 2018 Sep; 47(5):311-316.
Surveillance Imaging in Patients With Endometrial Cancer in First Remission.
Baechler S, Hobbs RF, Jacene HA, Bochud FO, Wahl RL, Sgouros G
Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med. 2010 Dec; 51(12):1878-84.
Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab.
Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma. Acad Radiol. 2010 Sep; 17(9):1175-85.
Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma.
Molecular imaging training for nuclear medicine residents. J Nucl Med. 2012 Apr; 53(4):655-7.
Molecular imaging training for nuclear medicine residents.
PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up. Semin Nucl Med. 2018 01; 48(1):37-49.
PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT. J Nucl Med. 2008 Oct; 49(10):1585-92.
Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT.
The relationship between patients' serum glucose levels and metabolically active brown adipose tissue detected by PET/CT. Mol Imaging Biol. 2011 Dec; 13(6):1278-83.
The relationship between patients' serum glucose levels and metabolically active brown adipose tissue detected by PET/CT.
Mosley C, Jacene HA, Holz A, Grand DJ, Wahl RL
Extramedullary hematopoiesis on F-18 FDG PET/CT in a patient with metastatic colon carcinoma. Clin Nucl Med. 2007 Nov; 32(11):878-80.
Extramedullary hematopoiesis on F-18 FDG PET/CT in a patient with metastatic colon carcinoma.
Jacene HA, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum O, Horton KM, Kamel I, Macura KJ, Tsai HL, Kowalski J, Wahl RL
Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med. 2009 Nov; 50(11):1760-9.
Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med. 2009 Jan; 50(1):8-17.
18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy.
Lyford-Pike S, Ha PK, Jacene HA, Saunders JR, Tufano RP
ORL; journal for oto-rhino-laryngology and its related specialties
Limitations of PET/CT in determining need for neck dissection after primary chemoradiation for advanced head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2009; 71(5):251-6.
Limitations of PET/CT in determining need for neck dissection after primary chemoradiation for advanced head and neck squamous cell carcinoma.
Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK
International journal of radiation oncology, biology, physics
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):e647-54.
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Subhas N, Patel PV, Pannu HK, Jacene HA, Fishman EK, Wahl RL
Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics. 2005 Jul-Aug; 25(4):1031-43.
Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET.